370 related articles for article (PubMed ID: 36453329)
1. Evaluation of antifungal susceptibility and clinical characteristics in fungal keratitis in a tertiary care center in North India.
Vanathi M; Naik R; Sidhu N; Ahmed NH; Gupta N; Tandon R
Indian J Ophthalmol; 2022 Dec; 70(12):4270-4283. PubMed ID: 36453329
[TBL] [Abstract][Full Text] [Related]
2. Antimicrobial susceptibility of Fusarium, Aspergillus, and other filamentous fungi isolated from keratitis.
Lalitha P; Shapiro BL; Srinivasan M; Prajna NV; Acharya NR; Fothergill AW; Ruiz J; Chidambaram JD; Maxey KJ; Hong KC; McLeod SD; Lietman TM
Arch Ophthalmol; 2007 Jun; 125(6):789-93. PubMed ID: 17562990
[TBL] [Abstract][Full Text] [Related]
3. Antifungal activities of posaconazole, ravuconazole, and voriconazole compared to those of itraconazole and amphotericin B against 239 clinical isolates of Aspergillus spp. and other filamentous fungi: report from SENTRY Antimicrobial Surveillance Program, 2000.
Pfaller MA; Messer SA; Hollis RJ; Jones RN;
Antimicrob Agents Chemother; 2002 Apr; 46(4):1032-7. PubMed ID: 11897586
[TBL] [Abstract][Full Text] [Related]
4. Necessity to identify the causative agent for appropriate treatment in fungal corneal ulcer: an in vitro study.
Gupta MK; Chandra A; Prakash P; Tilak R
J Mycol Med; 2018 Mar; 28(1):201-205. PubMed ID: 29398639
[TBL] [Abstract][Full Text] [Related]
5. In vitro susceptibility testing of Aspergillus spp. against voriconazole, itraconazole, posaconazole, amphotericin B and caspofungin.
Shi JY; Xu YC; Shi Y; Lü HX; Liu Y; Zhao WS; Chen DM; Xi LY; Zhou X; Wang H; Guo LN
Chin Med J (Engl); 2010 Oct; 123(19):2706-9. PubMed ID: 21034656
[TBL] [Abstract][Full Text] [Related]
6. Time-Kill Kinetics and In Vitro Antifungal Susceptibility of Non-fumigatus Aspergillus Species Isolated from Patients with Ocular Mycoses.
Öz Y; Özdemir HG; Gökbolat E; Kiraz N; Ilkit M; Seyedmousavi S
Mycopathologia; 2016 Apr; 181(3-4):225-33. PubMed ID: 26612621
[TBL] [Abstract][Full Text] [Related]
7. In vitro activities of posaconazole, fluconazole, itraconazole, voriconazole, and amphotericin B against a large collection of clinically important molds and yeasts.
Sabatelli F; Patel R; Mann PA; Mendrick CA; Norris CC; Hare R; Loebenberg D; Black TA; McNicholas PM
Antimicrob Agents Chemother; 2006 Jun; 50(6):2009-15. PubMed ID: 16723559
[TBL] [Abstract][Full Text] [Related]
8. Comparison of the Sensititre YeastOne and CLSI M38-A2 Microdilution Methods in Determining the Activity of Amphotericin B, Itraconazole, Voriconazole, and Posaconazole against Aspergillus Species.
Wang HC; Hsieh MI; Choi PC; Wu CJ
J Clin Microbiol; 2018 Oct; 56(10):. PubMed ID: 30093391
[TBL] [Abstract][Full Text] [Related]
9. Susceptibility patterns of amphotericin B, itraconazole, posaconazole, voriconazole and caspofungin for isolates causing invasive mould infections from the SENTRY Antifungal Surveillance Program (2018-2021) and application of single-site epidemiological cutoff values to evaluate amphotericin B activity.
Pfaller MA; Carvalhaes CG; Castanheira M
Mycoses; 2023 Oct; 66(10):854-868. PubMed ID: 37431241
[TBL] [Abstract][Full Text] [Related]
10. In vitro susceptibility of filamentous fungal isolates from a corneal ulcer clinical trial.
Lalitha P; Sun CQ; Prajna NV; Karpagam R; Geetha M; O'Brien KS; Cevallos V; McLeod SD; Acharya NR; Lietman TM;
Am J Ophthalmol; 2014 Feb; 157(2):318-26. PubMed ID: 24439440
[TBL] [Abstract][Full Text] [Related]
11. A comparative study of the in vitro susceptibilities of clinical and laboratory-selected resistant isolates of Aspergillus spp. to amphotericin B, itraconazole, voriconazole and posaconazole (SCH 56592).
Manavathu EK; Cutright JL; Loebenberg D; Chandrasekar PH
J Antimicrob Chemother; 2000 Aug; 46(2):229-34. PubMed ID: 10933645
[TBL] [Abstract][Full Text] [Related]
12. [Activity of butenafine against ocular pathogenic filamentous fungi in vitro].
Xu Y; Pang GR; Zhao DQ; Gao CW; Zhou LT; Sun ST; Wang BL; Chen ZJ
Zhonghua Yan Ke Za Zhi; 2010 Jan; 46(1):38-42. PubMed ID: 20388321
[TBL] [Abstract][Full Text] [Related]
13.
Oliveira Dos Santos C; Kolwijck E; van der Lee HA; Tehupeiory-Kooreman MC; Al-Hatmi AMS; Matayan E; Burton MJ; Eggink CA; Verweij PE
Antimicrob Agents Chemother; 2019 Aug; 63(8):. PubMed ID: 31182529
[TBL] [Abstract][Full Text] [Related]
14. Activities of E1210 and comparator agents tested by CLSI and EUCAST broth microdilution methods against Fusarium and Scedosporium species identified using molecular methods.
Castanheira M; Duncanson FP; Diekema DJ; Guarro J; Jones RN; Pfaller MA
Antimicrob Agents Chemother; 2012 Jan; 56(1):352-7. PubMed ID: 22083469
[TBL] [Abstract][Full Text] [Related]
15. In vitro evaluation of combination antifungal activity against Fusarium species isolated from ocular tissues of keratomycosis patients.
Li L; Wang Z; Li R; Luo S; Sun X
Am J Ophthalmol; 2008 Nov; 146(5):724-8. PubMed ID: 18707669
[TBL] [Abstract][Full Text] [Related]
16. Patterns of Antifungal Resistance in Adult Patients With Fungal Keratitis in South India: A Post Hoc Analysis of 3 Randomized Clinical Trials.
Prajna NV; Lalitha P; Krishnan T; Rajaraman R; Radnakrishnan N; Srinivasan M; Devi L; Das M; Liu Z; Zegans ME; Acharya NR; Porco TC; Lietman TM; Rose-Nussbaumer J
JAMA Ophthalmol; 2022 Feb; 140(2):179-184. PubMed ID: 35024776
[TBL] [Abstract][Full Text] [Related]
17. In vitro antifungal susceptibility of Fusarium species and Aspergillus fumigatus cultured from eleven horses with fungal keratitis.
Martinez PS; Whitley RD; Plummer CE; Richardson RL; Hamor RE; Wellehan JFX
Vet Ophthalmol; 2022 Sep; 25(5):376-384. PubMed ID: 35684950
[TBL] [Abstract][Full Text] [Related]
18. In vitro activity of a novel broad-spectrum antifungal, E1210, tested against Aspergillus spp. determined by CLSI and EUCAST broth microdilution methods.
Pfaller MA; Duncanson F; Messer SA; Moet GJ; Jones RN; Castanheira M
Antimicrob Agents Chemother; 2011 Nov; 55(11):5155-8. PubMed ID: 21844312
[TBL] [Abstract][Full Text] [Related]
19. Head-to-head comparison of the activities of currently available antifungal agents against 3,378 Spanish clinical isolates of yeasts and filamentous fungi.
Cuenca-Estrella M; Gomez-Lopez A; Mellado E; Buitrago MJ; Monzon A; Rodriguez-Tudela JL
Antimicrob Agents Chemother; 2006 Mar; 50(3):917-21. PubMed ID: 16495251
[TBL] [Abstract][Full Text] [Related]
20. In vitro susceptibility patterns of Aspergillus and Fusarium species isolated from equine ulcerative keratomycosis cases in the midwestern and southern United States with inclusion of the new antifungal agent voriconazole.
Pearce JW; Giuliano EA; Moore CP
Vet Ophthalmol; 2009; 12(5):318-24. PubMed ID: 19751493
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
